Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Condensed Consolidated Statements of Operations and Comprehensive Loss
Grant revenue	$ 354,621	$ 319,468	$ 1,296,764	$ 569,156
Operating expenses:
Research and development	2,846,399	2,122,603	7,004,451	5,581,802
General and administrative	1,605,238	1,719,715	5,385,923	6,784,388
Total operating expenses	4,451,637	3,842,318	12,390,374	12,366,190
Loss from operations	(4,097,016)	(3,522,850)	(11,093,610)	(11,797,034)
Other income (expense):
Interest income, net	348,741	321,215	1,014,518	913,846
Foreign currency (loss) gain	(35,494)	(2,880)	15,180	39,686
Total other income	313,247	318,335	1,029,698	953,532
Net loss	(3,783,769)	(3,204,515)	(10,063,912)	(10,843,502)
Other comprehensive (loss):
Foreign currency translation	23,557	(1,002)	6,526	(12,466)
Total comprehensive loss	$ (3,760,212)	$ (3,205,517)	$ (10,057,386)	$ (10,855,968)
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (0.64)	$ (0.86)	$ (1.88)	$ (3.03)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (0.64)	$ (0.86)	$ (1.88)	$ (3.03)
Weighted-average common shares outstanding, basic (in shares)	5,939,755	3,735,176	5,360,579	3,577,482
Weighted-average common shares outstanding, diluted (in shares)	5,939,755	3,735,176	5,360,579	3,577,482